NOAC Reduce Severe Bleeding Risk by 45 Percent : A study at the University of Gothenburg found that NOACs can reduce severe bleeding by 45% compared to Warren. Apixaban, also known as Eliquis, effectively treats blood clots without causing excessive bleeding. This applies to short-term and long-term treatments.
Katarina Glise Sandblad, a student at Sahlgrenska Academy at the University of Gothenburg, says using NOACs like apixaban instead of warfarin has clear advantages for treatment plans. The study’s findings are published in the Journal of Internal Medicine.
The study examined 45,000 patients prescribed blood-thinning medicines from 2014 to 2020. 43% of people received apixaban, while 40% received rivaroxaban, another type of NOAC medication. About 14% of people received the older medicine warfarin.
The study found that apixaban had the lowest bleeding risk, particularly in the first six months of treatment. Rivaroxaban had a lower risk than warfarin but not as low as apixaban. When examining longer treatments, no significant difference in bleeding risk was observed between apixaban and rivaroxaban. However, they couldn’t determine if this difference was due to chance or meaning. Both things had a small chance of bleeding, estimated at 1% per year.
Also Read : Ecoli in Grand Canyon: NPS Advises Boiling Water at Phantom Ranch Health Risks and Safety
The scientists found that patients on warfarin were typically older and had multiple health issues. We considered these factors in our analyses. Sandblad says warfarin is still used for conditions like atrial fibrillation, mechanical heart valves, or blood disorders, though less commonly now. Many patients could improve by switching to a NOAC.
NOACs are increasingly popular due to their reduced risks. This study confirms prior findings that NOACs have lower bleeding risks than warfarin. Blood thinners are commonly prescribed drugs. They are crucial for patients with blood clots in the legs and lungs.
This study may change how doctors prescribe anticoagulants. Breastfeeding patients or those with specific health conditions may still need a warfarin prescription. The study suggests many could switch to NOACs as a safer option for preventing blood clots.
Our Reader’s Queries
What is the bleeding risk of NOACs?
According to a study, NOACs can lead to an increase in gastrointestinal bleeding in patients with high risk factors. Rivaroxaban and high doses of edoxaban and dabigatran were found to significantly increase the risk of gastrointestinal bleeding when compared to warfarin. However, no such effects were observed with apixaban. Another study conducted by Gu et al. yielded similar results.
What is the lowest risk of bleeding with apixaban?
According to recent studies, Apixaban has been found to have the lowest risk of major bleeding. In fact, four different studies have reported that the risk of major bleeding is between 21% and 49% lower when compared to warfarin. These findings are presented in Table 3 and suggest that Apixaban may be a safer option for those who are at risk of bleeding complications.
What is the relative risk reduction of apixaban?
Apixaban has shown to significantly reduce the risk of thromboembolic events compared to warfarin in the regular dose group. The reduction was observed to be 23% (OR, 0.77; 95% CI, 0.640.93). However, in the reduced dose group, there was a 27% relative risk increase in any thromboembolic events. Additionally, major bleeding was significantly lower on apixaban compared to warfarin.
What are the odds of bleeding on Eliquis?
Apixaban, an anticoagulant, may cause bleeding as its most common adverse effect, with a frequency ranging from 1% to 10%. However, the risk of major bleeding is relatively low, at 3% or less. Clinically relevant nonmajor bleeding is also possible, with a frequency of 2% to 4%.